At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Regorafenibdrug
Likely dose
Regorafenib 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
In Brief
A Phase 2 clinical trial evaluating Regorafenib for Metastatic Colorectal Cancer. Completed, enrolled 27 participants across 4 sites.
Detailed Summary
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedJun 2015
Primary CompletionJul 2019
Study CompletionMar 2022
TodayJul 2026
First PostedJun 9, 2015
Enrollment StartMar 1, 2015
Primary CompletionJul 1, 2019
Study CompletionMar 9, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.1 years ago
Interventions
Regorafenibdrug
Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).